Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients.

Bibliographic Details
Authors: Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repository:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p4328
Online Access:https://i3pt.portalinvestigacion.com/publicaciones/4328
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181761067&doi=10.1158%2f1078-0432.CCR-23-0771&partnerID=40&md5=a4ac2303bc43a6a87bd90d23c549a28a
Access Level:Open access
Keyword:Bevacizumab
Carcinoma, Ovarian Epithelial
Chemotherapy, Adjuvant
Female
Forkhead Transcription Factors
Humans
Neoadjuvant Therapy
Ovarian Neoplasms
Tumor Microenvironment
bevacizumab
carboplatin
paclitaxel
transcription factor FOXP3
forkhead transcription factor
advanced cancer
Article
cancer resistance
cancer survival
CD4+ T lymphocyte
CD8+ T lymphocyte
cell subpopulation
clinical article
clinical outcome
controlled study
cytoreductive surgery
female
human
human cell
human tissue
immunofluorescence
immunohistochemistry
multiple cycle treatment
neoadjuvant chemotherapy
ovary cancer
progression free survival
regulatory T lymphocyte
tumor microenvironment
tumor-associated macrophage
adjuvant chemotherapy
neoadjuvant therapy
ovary carcinoma
ovary tumor
pathology
procedures
Description
Summary:The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients.

Similar Items